Search

Search Constraints

You searched for: Author/Creator Andreasen, Niels

Search Results

1. [O2–17–02]: DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS‐MAPTRX, THE FIRST TAU‐LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD. (1st July 2017)

2. [P2–211]: AMYLOID‐β42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID‐POSITIVE VERSUS AMYLOID‐NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT‐RISK FOR AD POPULATION. (1st July 2017)

3. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Issue 10 (19th December 2014)

4. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Issue 11 (9th February 2015)

5. Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid. (28th June 2010)

6. IC‐P‐108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. (1st July 2014)

7. Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total‐Aβ42/Aβ40 ratio. (29th September 2015)

9. O1–09–06: The 'CSF Alzheimer's profile': Easily said, but what do we mean?. (1st July 2013)